Lentivirus-based gene transfer vectors

• US 6,521,457 B2
• Filed: 07/06/2001
• Issued: 02/18/2003
• Est. Priority Date: 05/13/1997
• Status: Expired due to Term

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Olsen, John C.
• Primary Examiner(s): Guzo, David
• Assistant Examiner(s): Leffers, Jr., Gerald G.
• Application Number:
  US09/900,419
• Publication Number:
  US 20010044149A1
• Time in Patent Office: 592 Days
• Field of Search: 424/93.1, 424/93.21, 435/5, 435/6, 435/7.21, 435/455, 435/456, 435/465, 435/466, 435/362, 435/375, 435/320.1, 435/457, 435/325, 536/23.5, 536/23.72, 536/24.1, 536/23.1, 514/44
• US Class Current: 435/456
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2740/15043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/15052 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

A recombinant lentiviral vector expression system comprises a first vector that comprises a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome. The vector contains at least one defect in at least one gene encoding an EIAV structural protein, but is preferably a gag/pol expression vector. The expression system further comprises a second vector, also comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, and additionally containing a multiple cloning site wherein a heterologous gene may be inserted. The expression system also comprises a third vector which expresses a viral envelope protein. The first and third vectors are packaging signal-defective. When the expression system is transfected into a lentivirus-permissive cell, replication-defective EIAV particles may be produced, which particles are useful in delivering heterologous genes to a broad range of both dividing and non-dividing cells.

Claims

1. A method of delivering a heterologous nucleic acid sequence to a target cell, comprising the step of infecting the target cell with a replication-defective lentivirus particle comprising a recombinant Equine Infectious Anemia Virus (EIAV) nucleic acid sequence comprising (i) cis-acting sequence elements required for reverse transcription of the recombinant EIAV nucleic acid sequence, (ii) a competent packaging signal, and (iii) the heterologous nucleic acid sequence.

2. The method according to claim 1, wherein said target cell is a non-dividing target cell.

3. The method according to claim 1, wherein said target cell is a dividing target cell.

4. The method according to claim 1, wherein said target cell is a lymphocyte.

5. The method according to claim 1, wherein said target cell is an airway epithelial cell.

6. The method according to claim 5, wherein said target cell is a human airway epithelial cell.

7. The method according to claim 1, wherein said target cell is a neuronal cell.

8. The method according to claim 1, wherein said heterologous nucleic acid sequence encodes an antigenic protein or peptide.

9. The method according to claim 1, wherein said heterologous nucleic acid sequence encodes a reporter protein or peptide.

10. The method according to claim 1, wherein said heterologous nucleic acid sequence encodes a selectable marker.

11. The method according to claim 1, wherein said replication-defective lentivirus particle comprises an envelope protein that is not an EIAV envelope protein.

12. The method according to claim 11, wherein said replication-defective lentivirus particle comprises a vesicular stomatitis virus G glycoprotein.

13. The method according to claim 1, wherein said recombinant EIAV nucleic acid sequence is deficient for expression of at least one EIAV structural protein.

14. The method according to claim 13, wherein said recombinant EIAV nucleic acid sequence is deficient for expression of all of the EIAV structural proteins.

15. The method according to claim 1, wherein said recombinant EIAV nucleic acid sequence is deficient for expression of all of the EIAV non-structural proteins.

16. The method according to claim 1, wherein said step of infecting said target cell is carried out in vitro.

17. The method according to claim 1, wherein said step of infecting said target cell is carried out in vivo.

18. A method of delivering a heterologous nucleic acid sequence to a target cell, comprising the step of infecting the target cell with replication-defective lentivirus particles collected according to a method comprising:

(a) transfecting a lentivirus-permissive cell with;

(i) a first vector comprising an Equine Infectious Anemia Virus (EIAV) nucleic acid sequence encoding EIAV gag and EIAV pol, wherein said vector (1) comprises at least one defect in at least one gene encoding an EIAV structural protein, and (2) comprises a defective packaging signal;

(ii) a second vector comprising a recombinant EIAV nucleic acid sequence comprising (1) cis-acting sequence elements required for reverse transcription of the EIAV nucleic acid sequence, (2) a competent packaging signal, and (3) a heterologous nucleic acid sequence; and

(iii) a third vector comprising a nucleic acid sequence of a virus, wherein said third vector (1) expresses a viral envelope protein, and (2) comprises a defective packaging signal;

(b) growing the cell under cell culture conditions sufficient to allow production of replication-defective lentivirus particles in the cell; and

(c) collecting said replication-defective lentivirus particles from the cell.

19. The method according to claim 18, wherein said target cell is a human airway epithelial cell.

20. The method according to claim 18, wherein said step of infecting said target cell is carried out in vitro.

21. The method according to claim 18, wherein said step of infecting said target cell is carried out in vivo.

22. A method of delivering a heterologous nucleic acid sequence to a target cell, comprising the step of infecting said target cell with a replication-defective lentivirus particle comprising a recombinant EIAV nucleic acid sequence encoding (i) a promoter, and (ii) the heterologous nucleic acid sequence, and wherein said recombinant EIAV nucleic acid sequence is defective in encoding at least one EIAV structural protein to result in a replication-defective lentivirus particle.

23. The method according to claim 22, wherein said promoter is a heterologous promoter to said recombinant EIAV nucleic acid sequence.

24. The method according to claim 22, wherein said target cell is a non-dividing target cell.

25. The method according to claim 22, wherein said target cell is a dividing target cell.

26. The method according to claim 22, wherein said target cell is a lymphocyte.

27. The method according to claim 22, wherein said target cell is an airway epithelial cell.

28. The method according to claim 27, wherein said target cell is a human airway epithelial cell.

29. The method according to claim 22, wherein said target cell is a neuronal cell.

30. The method according to claim 22, wherein said heterologous nucleic acid sequence encodes an antigenic protein or peptide.

31. The method according to claim 22, wherein said heterologous nucleic acid sequence encodes a reporter protein or peptide.

32. The method according to claim 22, wherein said heterologous nucleic acid sequence encodes a selectable marker.

33. The method according to claim 22, wherein said replication-defective lentivirus particle comprises an envelope protein that is not an EIAV envelope protein.

34. The method according to claim 33, wherein said replication-defective lentivirus particle comprises a vesicular stomatitis virus G glycoprotein.

35. The method according to claim 22, wherein said recombinant EIAV nucleic acid sequence is deficient for expression of all of the EIAV structural proteins.

36. The method according to claim 22, wherein said recombinant EIAV nucleic acid sequence is deficient for expression of all of the EIAV non-structural proteins.

37. The method according to claim 22, wherein said step of infecting said target cell is carried out in vitro.

38. The method according to claim 22, wherein said step of infecting said target cell is carried out in vivo.